12:06 PM EST - Haemacure Corp. : a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products reported its second quarter results. Revenues amounted to $28,368, as compared to $24,757 for the same quarter last year. The consolidated net loss for the quarter amounted to $2.5 million, or $0.02 per share, as compared to $1.3 million, or $0.01 per share, for the same quarter last year. Haemacure Corp.
shares T.HAE are trading off 9 percent at $0.15.
